Keywords:
Respiratory organs-Diseases-Treatment.
;
Electronic books.
Description / Table of Contents:
Handbook of Lung Targeted Drug Delivery Systems: Recent Trends and Clinical Evidences covers every aspect of the drug delivery to lungs, the physiology and pharmacology of the lung, modelling for lung delivery, drug devices focused on lung treatment, regulatory requirements, and recent trends in clinical applications.
Type of Medium:
Online Resource
Pages:
1 online resource (693 pages)
Edition:
1st ed.
ISBN:
9781000450804
URL:
https://ebookcentral.proquest.com/lib/geomar/detail.action?docID=6713927
Language:
English
Note:
Intro -- Half Title -- Title Page -- Copyright Page -- Dedication -- Contents -- Editors -- List of Contributors -- Foreword -- Preface -- 1. Introduction to Lung Physiology from a Drug Delivery Perspective -- 1.1 Introduction -- 1.1.1 Brief Introduction to Nanotechnology and Nanoparticle Mediated Drug Delivery -- 1.1.2 The Inhalation Route -- 1.2 Anatomy and Physiology of Lungs -- 1.3 Nanoparticle-based Systems for Pulmonary Application -- 1.4 Treatment of Chronic Diseases Through the Pulmonary Route -- References -- 2. Introduction to Pharmacology of the Lung from a Drug Delivery Perspective -- 2.1 The Respiratory Tract: An Overview -- 2.1.1 The Conducting Zone -- 2.1.2 The Respiratory Zone -- 2.2 Respiratory Pathology -- 2.2.1 Asthma Overview -- 2.2.1.1 Classifications and Goals of Treatment -- 2.2.2 Chronic Bronchitis Overview -- 2.2.2.1 Chronic Bronchitis Goals of Treatment -- 2.2.3 Chronic Obstructive Pulmonary Disease (COPD) Overview -- 2.2.3.1 COPD Goals of Treatment -- 2.2.4 Cystic Fibrosis Overview -- 2.2.4.1 Cystic Fibrosis Goals of Treatment -- 2.3 Respiratory Drug Delivery Mechanisms -- 2.3.1 Therapeutic Administrations of Inhaled Medications -- 2.3.2 Inhaler Devices -- 2.3.2.1 Pressurized Metered Dose Inhaler -- 2.3.2.2 Dry Powder Inhaler -- 2.3.2.3 Respimat Soft Mist Inhaler -- 2.3.2.4 Nebulizers -- 2.3.4 Patient Education -- 2.4 Overview of Inhaled Therapies -- 2.4.1 β2 Adrenergic Agonists -- 2.4.1.1 β2 Adrenergic Agonists Subtypes: SABA and LABA -- 2.4.1.2 β2 Adrenergic Agonists Side Effects -- 2.4.2 Corticosteroids -- 2.4.2.1 Corticosteroids Side Effects -- 2.4.3 Anti-cholinergic Agents -- 2.4.3.1 Anti-cholinergic Side Effects -- 2.5 Overview of Oral Therapies -- 2.5.1 Mucolytics/Expectorants -- 2.5.1.1 Mucolytics/Expectorants Side Effects -- 2.5.2 Phosphodiesterase (PDE) Inhibitors.
,
2.5.2.1 Phosphodiesterase (PDE) Inhibitor Side Effects -- 2.5.3 Macrolides -- 2.5.3.1 Macrolide Side Effects -- 2.5.4 Leukotriene Modifiers -- 2.5.4.1 Leukotriene Modifier Side Effects -- 2.6 Recommended Therapies for Asthma and COPD Management -- 2.6.1 Asthma -- 2.6.2 COPD -- 2.7 Systemic Drug Delivery via the Lungs -- References -- 3. Mechanism and Ways of Pulmonary Drug Administration -- 3.1 Introduction -- 3.2 Mechanisms of Drug Permeation into the Lungs -- 3.3 Deposition of Aerosol Particles in the Respiratory Airways -- 3.3.1 Mechanisms of Particle Deposition in the Respiratory Airways -- 3.3.1.1 Inertial Impaction -- 3.3.1.2 Sedimentation -- 3.3.1.3 Brownian Diffusion -- 3.3.2 Factors Affecting Particle Deposition -- 3.3.3 Effect of Particle Size -- 3.1 Respiratory Clearance of Inhaled Particles -- 3.4.1 Mucociliary Clearance -- 3.4.2 Alveolar Clearance -- 3.5 Ways of Pulmonary Drug Administration -- 3.5.1 Pressurized Metered Dose Inhalers -- 3.5.2 Dry Powder Inhalers (DPIs) -- 3.5.3 Nebulizers -- 3.6 Conclusion -- References -- 4. Transepithelial Route of Drug Delivery through the Pulmonary System -- 4.1 Introduction -- 4.2 Macrostructure of Lungs -- 4.3 Drug Targeting: Anatomical Sites -- 4.3.1 Anatomical Barriers to Drug Flow -- 4.4 Drug Deposition: Mechanism -- 4.4.1 Physiological Factors Affecting Deposition -- 4.4.1.1 Effect of Diseased State on Drug Deposition -- 4.5 Levels of Clearance -- 4.5.1 The Mechanism to Overcome Pulmonary Clearance -- 4.6 Airway Cells, Pulmonary Circulation, and Receptors: Importance and Function -- 4.6.1 Airway Cells -- 4.6.2 Airway Receptors -- 4.6.3 Effect of Blood Circulation on Drug Delivery -- 4.7 Pulmonary Drug Delivery: Dissolution, Metabolism, Absorption, and Clearance -- 4.7.1 Pulmonary Dissolution -- 4.7.2 Pulmonary Absorption -- 4.7.3 Mucociliary Clearance -- 4.7.4 Pulmonary Retention.
,
4.8 Affect of Lung Physiology and Pathophysiology on Drug Absorption -- 4.8.1 Pharmacokinetics of Nasal Drug Delivery -- 4.8.2 Pharmacokinetic Processes of Oral, Intravenous, and Inhalation Administration -- 4.9 Pulmonary Drug Delivery: Different Molecular Size -- 4.9.1 Smaller Molecules Used to Deliver Drugs through the Pulmonary Route -- 4.9.2 Large Microporous Molecules -- 4.9.3 Pulmonary Delivery of Large Peptides and High Molecular Weight Drugs -- 4.9.3.1 Insulin -- 4.9.3.2 Low Molecular Weight Heparins (LMWH) -- 4.10 Nanocarriers in Pulmonary Delivery of Drugs -- References -- 5. Understanding the Pharmacokinetics and Pharmacodynamics of Lung and Lung Drug Delivery -- 5.1 Introduction -- 5.2 Pharmacokinetics of the Lung and Lung Drug Delivery -- 5.2.1 Absorption of Drugs in the Lungs -- 5.2.2 Elimination of Drugs in the Lungs -- 5.3 Pharmacodynamics of Lung Drug Delivery: Recent Trends and Clinical Evidence -- 5.3.1 Inhaled Antibiotics -- 5.3.2 Hormones Administered through the Pulmonary Route -- 5.3.2.1 Inhaled Insulins -- 5.3.2.2 Inhaled Growth Hormone -- 5.3.3 Inhaled Corticosteroids -- References -- 6. Chronic Lung Diseases: Treatment, Challenges, and Solutions -- 6.1 Introduction -- 6.1.1 Types of Chronic Lung Diseases -- 6.1.1.1 Asthma -- 6.1.1.1.1 Pathophysiology -- 6.1.1.2 Chronic Bronchitis -- 6.1.1.2.1 Pathophysiology -- 6.1.1.3 Chronic Obstructive Pulmonary Disease (COPD) -- 6.1.1.3.1 Risk Factors -- 6.1.1.3.2 Pathophysiology -- 6.2 Different Treatment Strategies of Chronic Lung Diseases along with Their Pharmacology -- 6.2.1 Current Treatment Strategy for Lung Diseases -- 6.2.1.1 Treatment of Chronic Asthma (26-28) -- 6.2.1.2 Current Treatment Strategy of Bronchitis (29,30) -- 6.2.1.3 Current Treatment Strategy of COPD (31-34) -- 6.2.2 Bioactive Compounds -- 6.2.2.1 Bioactive Compounds for Treatment of Asthma (36,37).
,
6.2.2.2 Bioactive Compounds for Treatment of Chronic Bronchitis (38, 39) -- 6.2.2.3 Bioactive Compounds for Treatment of COPD (40, 41) -- 6.3 Conventional Drug Delivery Systems for Mitigating Chronic Lung Diseases -- 6.3.1 Material Based -- 6.3.1.1 Multifunctional Nanocarriers -- 6.3.1.2 Hydrogels -- 6.3.1.3 Micelle -- 6.3.1.4 Dendrimer -- 6.3.1.5 Liposomes -- 6.4.2 Administration Based -- 6.4.2.1 Pulmonary Drug Administration -- 6.4.2.2 Inhalation Delivery -- 6.4.2.3 Systematic Delivery -- 6.4.3 Different Drug Delivery Systems for Different Categories of Patients -- 6.4.3.1 Elderly Patients -- 6.4.3.2 Pregnant Patients -- 6.4.3.3 Obese Patients -- 6.4 Recent Development in Targeted Drug Delivery Systems for Mitigating Chronic Lung Diseases -- 6.5 Challenges and Solutions -- 6.5.1 Asthma -- 6.5.2 Bronchial Disorders -- 6.5.3 COPD -- 6.6 Future Prospects -- 6.7 Conclusion -- Acknowledgments -- References -- 7. Understanding of Lung Diseases with a Focus on Applications of Nano-particulate Drug Delivery Systems -- 7.1 Introduction -- 7.2 Lung Diseases: A Brief Insight -- 7.2.1 Obstructive Lung Disease (OLD) -- 7.2.2 Restrictive Lung Disease (RLD) -- 7.2.3 Pleural Lung Disease -- 7.2.4 Vascular Lung Disease -- 7.3 Management and Treatment of Lung Diseases -- 7.3.1 Pharmacological Approaches to Treating Lung Diseases -- 7.3.1.1 Bronchodilators -- 7.3.1.1.1 Beta-2 Agonists -- 7.3.1.1.2 Anti-muscarinic Drugs -- 7.3.1.1.3 Methylxanthines -- 7.3.1.1.4 Combination Bronchodilator Therapy -- 7.3.1.2 Anti-Inflammatory Agents -- 7.3.1.2.1 Corticosteroids -- 7.3.1.2.2 Phosphodiesterase-4-Inhibitors (PDE4 Inhibitors) -- 7.3.1.2.3 Antibiotics -- 7.3.1.2.4 Leukotriene Modulators -- 7.3.1.2.5 Antioxidants -- 7.3.1.3 Vaccinations -- 7.3.1.4 Nicotine Replacement Therapy -- 7.3.2 Non-pharmacological Approach.
,
7.3.2.1 Oxygen Therapy and Ventilatory Support -- 7.3.2.1.1 Oxygen Therapy -- 7.3.2.1.2 Ventilatory Support -- 7.3.2.2 Surgical Interventions -- 7.3.2.2.1 Lung Volume Reduction Surgery -- 7.3.2.2.2 Bullectomy -- 7.3.2.2.3 Lung Transplantation -- 7.3.2.2.4 Bronchoscopic Interventions -- 7.3.2.3 Education and Self-Management -- 7.3.2.4 Pulmonary Rehabilitation Programs -- 7.3.2.5 Exercise Training -- 7.3.2.6 Self-Management Education -- 7.3.2.7 Palliative Care -- 7.4 Application of Nano-Drug Delivery Systems in Lung Diseases -- 7.4.1 Characteristics of Pulmonary Nano-Drug Delivery -- 7.4.1.1 Pulmonary Distribution of Drug -- 7.4.1.2 Improved Solubility/Dissolution Rate -- 7.4.1.3 Sustained Release Properties -- 7.4.1.4 Delivery of Macromolecules -- 7.4.1.5 Internalization by Cells -- 7.4.2 Fate of Nanocarriers in the Lungs -- 7.4.3 Strategies to Overcome Clearance of Nanocarriers -- 7.4.4 Nano-Formulation for Drug Delivery to Lungs -- 7.4.4.1.1 Polymeric Nanoparticles -- 7.4.4.1.2 Antigenic Nanoparticles -- 7.4.4.1.3 Solid Lipid Nanoparticles -- 7.4.4.1.4 Depots -- 7.4.4.1.5 Pressure Sensitive Metered Dose Inhalers (pMDIs) -- 7.4.4.2 Vesicular Nano-Drug Delivery to Lungs -- 7.4.4.2.1 Liposomes -- 7.4.4.2.2 Nanoemulsions -- 7.4.4.3 Advantage of Particulate Drug Delivery to Lungs -- 7.5 Conclusion -- References -- 8. Model for Pharmaceutical aerosol transport through stenosis airway -- 8.1 Introduction -- 8.2 Numerical Method -- 8.3 Geometrical Development -- 8.4 Grid Generation and Validation -- 8.5 Results and Discussion -- 8.5.1 Effects of Aging Cases -- 8.5.1.1 Airflow Analysis -- 8.5.1.1.1 Velocity Profiles -- 8.5.1.1.2 Velocity Contours -- 8.5.1.2 Pressure Drop -- 8.5.1.2.1 Pressure Distribution -- 8.5.1.2.2 Pressure Contours -- 8.5.1.3 Wall Shear -- 8.5.1.4 Turbulent Intensity -- 8.5.1.5 Particle Transport.
,
8.5.1.5.1 Deposition Efficiency.
Permalink